Applications of Dynamic Contrast-Enhanced MRI in Oncology Drug Development

  • Gordon C. Jayson
  • John C. Waterton
Part of the Medical Radiology book series (MEDRAD)


Clin Oncol Magn Reson Image Signal Intensity Change Contrast Agent Concentration Drug Developer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Baba Y, Furusawa M, Murakami R, Yokoyama T, Sakamoto Y, Nishimura R, Yamashita Y, Takahashi M, Ishikawa T (1997) Role of dynamic MRI in the evaluation of head and neck cancers treated with radiation therapy. Int J Radiat Oncol Biol Phys 37:783–787CrossRefPubMedGoogle Scholar
  2. Barentsz JO, Berger-Hartog O, Witjes JA, Hulsbergen-van der Kaa C, Oosterhof GO, VanderLaak JA, Kondacki H, Ruijs SH (1998) Evaluation of chemotherapy in advanced urinary bladder cancer with fast dynamic contrast-enhanced MR imaging. Radiology 207:791–797PubMedGoogle Scholar
  3. Blasberg RG, Roelcke U, Weinreich R, Beattie B, von Ammon K, Yonekawa Y, Landolt H, Guenther I, Crompton NE, Vontobel P, Missimer J, Maguire RP, Koziorowski J, Knust EJ, Finn RD, Leenders KL (2000) Imaging brain tumor proliferative activity with [124I]iododeoxyuridine. Cancer Res 60:624–635PubMedGoogle Scholar
  4. Buadu LD, Murakami J, Murayama S, Hashiguchi N, Sakai S, Masuda K, Toyoshima S, Kuroki S, Ohno S (1996) Breast lesions: correlation of contrast medium enhancement patterns on MR images with histopathologic findings and tumor angiogenesis. Radiology 200:639–649PubMedGoogle Scholar
  5. Buckley DL, Drew PJ, Mussurakis S, Monson JR, Horsman A (1997) Microvessel density of invasive breast cancer assessed by dynamic Gd-DTPA enhanced MRI. J Magn Reson Imaging 7:461–464PubMedGoogle Scholar
  6. Checkley D, Tessier J, Kendrew J et al (2003) Dynamic contrast-enhanced MRI as a marker of biological effect: a study of a human prostate tumor xenograft treated with the VEGF signaling inhibitor ZD6474. Br J Cancer 89:1889–1895.CrossRefPubMedGoogle Scholar
  7. Cooper RA, Carrington BM, Loncaster JA et al. (2000) Tumour oxygenation levels correlate with dynamic contrast-enhanced magnetic resonance imaging parameters in carcinoma of the cervix. Radiother Oncol 57:53–59CrossRefPubMedGoogle Scholar
  8. Cristofanilli M, Charnsangavej C, Hortobagyi GN (2002) Angiogenesis modulation in cancer research: novel clinical approaches. Nat Rev Drug Discov 1:415–426CrossRefPubMedGoogle Scholar
  9. Devries AF, Griebel J, Kremser C, Judmaier W, Gneiting T, Kreczy A, Ofner D, Pfeiffer KP, Brix G, Lukas P (2001) Tumor microcirculation evaluated by dynamic magnetic resonance imaging predicts therapy outcome for primary rectal carcinoma. Cancer Res 61:2513–2516PubMedGoogle Scholar
  10. Dowlati A, Robertson K, Cooney M, Petros WP, Stratford M, Jesberger J, Rafie N, Overmoyer B, Makkar V, Stambler B, Taylor A, Waas J, Lewin JS, McCrae KR, Remick SC (2002) A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 62:3408–3416PubMedGoogle Scholar
  11. Eder JP, Supko JG, Clark JW, Puchalski TA, Garcia-Carbonero R, Ryan DP, Shulman LN, Proper J, Kirvan M, Rattner B, Connors S, Keogan MT, Janicek MJ, Fogler WE, Schnipper L, Kinchla N, Sidor C, Phillips E, Folkman J, Kufe DW (2002) Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol 20:3772–3784CrossRefPubMedGoogle Scholar
  12. Evelhoch J, Brown T, Chenevert T et al. (2000) Consensus recommendation for acquisition of dynamic contrasted-enhanced MRI data in oncology. Proc Int Soc Magn Reson Med Eighth Scientific Meeting and Exhibition, p 1439Google Scholar
  13. Evelhoch J, Lorusso P, Delproposto Z et al. (2002) Dynamic contrast-enhanced MRI evaluation of the effects of ZD6126 on tumor vasculature in a phase I clinical trial. Proc Int Soc Magn Reson Med Tenth Scientific Meeting and Exhibition, p 2095Google Scholar
  14. Federal Register (1997) ICH harmonised tripartite guideline for good clinical practice, vol. 62, pp 25691–25709Google Scholar
  15. Galbraith SM, Lodge MA, Taylor NJ et al. (2001) Combretastatin A4 phosphate (CA4P) reduces tumor blood flow in animals and man, demonstrated by MRI. Proc Amer Soc Clin Oncol 20:278 (abstract)Google Scholar
  16. Galbraith SM, Rustin GJ, Lodge MA, Taylor NJ, Stirling JJ, Jameson M, Thompson P, Hough D, Gumbrell L, Padhani AR (2002) Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J Clin Oncol 20:3826–3840CrossRefPubMedGoogle Scholar
  17. Hasan J, Jayson GC (2001) VEGF antagonists. Expert Opin Biol Ther 1:703–718PubMedGoogle Scholar
  18. Hawighorst H, Knapstein PG, Weikel W, Knopp MV, Zuna I, Knof A, Brix G, Schaeffer U, Wilkens C, Schoenberg SO, Essig M, Vaupel P, van Kaick G (1997) Angiogenesis of uterine cervical carcinoma: characterization by pharmacokinetic magnetic resonance parameters and histological microvessel density with correlation to lymphatic involvement. Cancer Res 57:4777–4786PubMedGoogle Scholar
  19. Hawighorst H, Knapstein PG, Knopp MV, Weikel W, Brix G, Zuna I, Schönberg SO, Essig M, Vaupel P, van Kaick G (1998) Uterine cervical carcinoma: comparison of standard and pharmacokinetic analysis of time-intensity curves for assessment of tumor angiogenesis and patient survival. Cancer Res 58:3598–3602PubMedGoogle Scholar
  20. Hawighorst H, Weikel W, Knapstein PG, Knopp MV, Zuna I, Schönberg SO, Vaupel P, van Kaick G (1998) Angiogenic activity of cervical carcinoma: assessment by functional magnetic resonance imaging-based parameters and a histomorphological approach in correlation with disease outcome. Clin Cancer Res 4:2305–2312PubMedGoogle Scholar
  21. Hawighorst H, Knapstein PG, Knopp MV, Vaupel P, van Kaick G (1999) Cervical carcinoma: standard and pharmacokinetic analysis of time-intensity curves for assessment of tumor angiogenesis and patient survival. MAGMA 8:55–62CrossRefPubMedGoogle Scholar
  22. Herbst RS, Hess KR, Tran HT, Tseng JE, Mullani NA, Charnsangavej C, Madden T, Davis DW, McConkey DJ, O'Reilly MS, Ellis LM, Pluda J, Hong WK, Abbruzzese JL (2002) Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 20:3792–3803CrossRefPubMedGoogle Scholar
  23. Herbst RS, Mullani NA, Davis DW, Hess KR, McConkey DJ, Charnsangavej C, O'Reilly MS, Kim HW, Baker C, Roach J, Ellis LM, Rashid A, Pluda J, Bucana C, Madden TL, Tran HT, Abbruzzese JL (2002) Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J Clin Oncol 20:3804–3814CrossRefPubMedGoogle Scholar
  24. Hofstra L, Liem IH, Dumont EA, Boersma HH, van Heerde WL, Doevendans PA, De Muinck E, Wellens HJ, Kemerink GJ, Reutelingsperger CP, Heidendal GA (2000) Visualisation of cell death in vivo in patients with acute myocardial infarction. Lancet 356:209–212CrossRefPubMedGoogle Scholar
  25. Hoskin, P.J., Saunders, M.I., Goodchild, K. et al (1999) Dynamic contrast enhanced magnetic resonance scanning as a predictor of response to accelerated radiotherapy for advanced head and neck cancer. Br J Radiol 72:1093–1098PubMedGoogle Scholar
  26. Hulka CA, Edmister WB, Smith BL, Tan L, Sgroi DC, Campbell T, Kopans DB, Weisskoff RM (1997) Dynamic echo-planar imaging of the breast: experience in diagnosing breast carcinoma and correlation with tumor angiogenesis. Radiology 205:837–842PubMedGoogle Scholar
  27. Ikeda O, Yamashita Y, Morishita S, Kido T, Kitajima M, Okamura K, Fukuda S, Takahashi M (1999) Characterization of breast masses by dynamic enhanced MR imaging. A logistic regression analysis. Acta Radiol 40:585–592PubMedGoogle Scholar
  28. Jackson A, Haroon H, Zhu XP, Li KL, Thacker NA, Jayson G (2002) Breath-hold perfusion and permeability mapping of hepatic malignancies using magnetic resonance imaging and a first-pass leakage profile model. NMR Biomed 15:164–173CrossRefPubMedGoogle Scholar
  29. Jackson A, Jayson GC, Li KL, Zhu XP, Checkley DR, Tessier JJ, Waterton JC (2003) Reproducibility of quantitative dynamic contrast-enhanced MRI in newly presenting glioma. Br J Radiol 76:153–162CrossRefPubMedGoogle Scholar
  30. Jayson GC, Zweit J, Jackson A et al. (2002) Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst 94:1484–1493PubMedGoogle Scholar
  31. Knopp MV, Weiss E, Sinn HP et al. (1999) Pathophysiologic basis of contrast enhancement in breast tumors. J Magn Reson Imaging 10:260–266CrossRefPubMedGoogle Scholar
  32. Kuenen BC, Rosen L, Smit EF et al. (2002) Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol 20:1657–1667CrossRefPubMedGoogle Scholar
  33. Leach MO, Brindle KM, Evelhoch JL et al. (2003) Assessment of anti-angiogenic and anti-vascular therapeutics using Magnetic Resonance Imaging: recommendations for appropriate methodology for clinical trials. Proc Int Soc Magn Reson Med Eleventh Scientific Meeting and Exhibition, p 1268Google Scholar
  34. Lesko LJ, Atkinson AJ Jr (2001) Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Annu Rev Pharmacol Toxicol 41:347–366CrossRefPubMedGoogle Scholar
  35. Matsubayashi R, Matsuo Y, Edakuni G, Satoh T, Tokunaga O, Kudo S (2000) Breast masses with peripheral rim enhancement on dynamic contrast-enhanced MR images: correlation of MR findings with histologic features and expression of growth factors. Radiology 217:841–848PubMedGoogle Scholar
  36. Medved M, Maceneany P, Karxzmar H et al. (2002) Contrast agent dynamics as an early marker of antiangiogenic agent action. Proc Int Soc Magn Reson Med Tenth Scientific Meeting, p 2099Google Scholar
  37. Morgan B, Thomas AL, Drevs J et al. (2003) Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 21:3955–3964CrossRefPubMedGoogle Scholar
  38. Nagashima T, Suzuki M, Yagata H et al. (2002) Dynamic-enhanced MRI predicts metastatic potential of invasive ductal breast cancer. Breast Cancer 9:226–230PubMedGoogle Scholar
  39. Pradel C, Siauve N, Bruneteau G et al. (2003) Reduced capillary perfusion and permeability in human tumour xenografts treated with the VEGF signalling inhibitor ZD4190: an in vivo assessment using dynamic MR imaging and macromolecular contrast media. Magn Reson Imaging 21:845–851CrossRefPubMedGoogle Scholar
  40. Robinson SP, Mcintyre SJO, Checkley D et al. (2003) Tumour dose response to the anti-vascular agent ZD6126 assessed by magnetic resonance imaging. Br J Cancer 88:1592–1597CrossRefPubMedGoogle Scholar
  41. Ruehm SG, Christina H, Violas X Corot C, Debatin JF (2002) MR angiography with a new rapid-clearance blood pool agent: Initial experience in rabbits. Magn Reson Med 48:844–851PubMedGoogle Scholar
  42. Stomper PC, Winston JS, Herman S, Klippenstein DL, Arredondo MA, Blumenson LE (1997) Angiogenesis and dynamic MR imaging gadolinium enhancement of malignant and benign breast lesions. Breast Cancer Res Treat 45:39–46CrossRefPubMedGoogle Scholar
  43. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216PubMedGoogle Scholar
  44. Thomas A, Morgan B, Drevs J et al (2001) Pharmacodynamic results using dynamic contrast enhanced magnetic resonance imaging, of 2 phase 1 studies of the VEGF inhibitor PTK787/ZK 222584 in patients with liver metastases from colorectal cancer. Proc Amer Soc Clin Oncol 20:abstr 279Google Scholar
  45. Tofts PS, Kermode AG (1991) Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn Reson Med 17:357–367PubMedGoogle Scholar
  46. Tofts PS, Brix G, Buckley DL et al. (1999) Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 10:223–232CrossRefPubMedGoogle Scholar
  47. Tynninen O, Aronen HJ, Ruhala M et al. (1999) MRI enhancement and microvascular density in gliomas. Correlation with tumor cell proliferation. Invest Radiol 34:427–434PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2005

Authors and Affiliations

  • Gordon C. Jayson
    • 1
  • John C. Waterton
    • 2
  1. 1.Cancer Research UK, Department of Medical OncologyChristie Hospital NHS TrustWithington, ManchesterUK
  2. 2.Enabling Science & Technology, AstraZenecaMacclesfield, CheshireUK

Personalised recommendations